trending Market Intelligence /marketintelligence/en/news-insights/trending/FBZIlMtQstSQdwFP_KmvVA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

US FDA approves Sanofi, Regeneron's eczema drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


US FDA approves Sanofi, Regeneron's eczema drug

Regeneron Pharmaceuticals Inc. and Sanofi SA received U.S. FDA approval for Dupixent injection for the treatment of atopic dermatitis, the most common form of eczema.

The drug is approved to treat adults with moderate to severe atopic dermatitis when the disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Dupixent was evaluated by the FDA with priority review after the regulatory body's breakthrough therapy designation for the drug in 2014.

Regeneron and Sanofi Genzyme, Sanofi's specialty care global business unit, will market the drug in the U.S. The drug is expected to be available to patients and providers in the U.S. in the week of March 27.

U.K. regulators have granted the drug an investigational treatment status for atopic dermatitis, which means that patients can buy the drug before it is granted marketing authorization in the U.K.